ArticleBMC bioinformatics2025
ESAE-SDA: ensemble sparse autoencoder framework for epigenomics-informed snoRNA-disease associations prediction.
Article in BMC bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small nucleolar RNAs (snoRNAs), a class of non-coding RNAs broadly distributed in eukaryotes, are emerging as pivotal regulators in the field of epigenomics. In addition to guiding 2'-O-methylation and pseudouridylation modifications at specific rRNA sites to maintain ribosomal stability and support protein synthesis, snoRNAs have been increasingly implicated in epigenetic regulation, influencing gene expression, chromatin architecture, and RNA modification patterns. Accurate identification of potential snoRNA-disease associations (SDAs) is therefore essential for understanding epigenomic dysregulation in complex diseases and facilitating early intervention and drug repurposing. Although artificial intelligence (AI) methods have advanced SDA prediction, they are still hindered by issues such as sample imbalance and high false-negative rates. To address these challenges, we propose ESAE-SDA, a novel model integrating sparse autoencoders with an ensemble learning framework. ESAE-SDA first constructs a comprehensive snoRNA-disease representation using multi-source similarity metrics. It then applies k-means clustering to select high-confidence negative samples and employs a deep sparse autoencoder with sparsity constraints to learn compact, discriminative embeddings. Finally, multiple GNN-based learners are independently trained on dynamically resampled data, and ensemble inference is performed via weighted fusion, substantially enhancing robustness and generalization. Experiments on a public SDA dataset demonstrate that ESAE-SDA consistently outperforms state-of-the-art methods. Notably, a case study on ophthalmic diseases highlights the model's ability to uncover epigenetically relevant snoRNAs with potential regulatory and therapeutic significance, underscoring its value in epigenomics-driven disease research and target discovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.